Patent intelligence · US
US 9220735
Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
Patent details — US 9220735
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 29, 2015
- Expiration
- Dec 24, 2035
- Applicant
- AKER BIOMARINE ANTARCTIC AS
- Claims
- 5
- CPC classes
- A61K, A61K31/202, A61K31/215, A61K31/683
Quick answer
US 9220735 (Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders) is held by AKER BIOMARINE ANTARCTIC AS. Status: granted. Granted Dec 29, 2015. Expires Dec 24, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AKER BIOMARINE ANTARCTIC AS
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/202, A61K31/215, A61K31/683, A61K35/612, A61P
More from AKER BIOMARINE ANTARCTIC AS
Related pharmaceutical patents in our USPTO index.
-
US 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted -
US 12331293
Bispecific antisense oligonucleotides for dystrophin exon skipping
granted -
US 12239692
Adeno-associated virus factor VIII vectors
granted -
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted -
US 12214015
Use of c-type natriuretic peptide variants to treat osteoarthritis
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12188058
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 12076372
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted
Frequently asked questions
What is US patent 9220735?
US 9220735 (Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders) is held by AKER BIOMARINE ANTARCTIC AS. Status: granted. Granted Dec 29, 2015. Expires Dec 24, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9220735?
AKER BIOMARINE ANTARCTIC AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.
When does US 9220735 expire?
Our index shows an expiration date of Dec 24, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.